DOI
10.3389/fonc.2022.1026747
Prognostic and predictive factors of secondary gliosarcoma: A single-institution series of 18 cases combined with 89 cases from literature
作者地址
Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China
通讯作者
Julei Wang; Liang Wang
来源期刊
Frontiers in Oncology
摘要
Introduction: Secondary gliosarcomas (SGS) are rare malignancies that are diagnosed subsequent to pre-existing glioma. Clinical features and optimal treatment strategies for SGS have not been conclusively established. This study aimed to assess the clinicopathological features and outcomes of SGS.
Methods: We assessed the clinicopathological features and outcomes of SGS via retrospective analysis of data for SGS patients at Tangdu Hospital. Data from SGS patients in prior publications were also analyzed in accordance with PRISMA guidelines.
Results: Eighteen SGS patients who had been treated at Tangdu Hospital between 2013 and 2020 were enrolled in this study. Additional 89 eligible SGS patients were identified from 39 studies. The median age for the patients was 53 years old, and the most common location was the temporal lobe. The most common initial diagnosis was glioblastoma (GBM) (72.0%). Radiology revealed enhanced masses in 94.8% (73/77) of patients. Ten patients (10/107, 9.35%) had extracranial metastases at or after SGS diagnosis. Patients with initial diagnosis of non-GBM and who were younger than 60 years of age were significantly associated with a long duration of disease progression to SGS. After SGS diagnosis, patients with initial non-GBM diagnosis, gross total resection and chemoradiotherapy exhibited prolonged survival outcomes. Patients who had been initially diagnosed with GBM and received both chemoradiotherapy and active therapy after disease progression to SGS, had a significantly longer overall survival than patients who did not.
Conclusion: Initial diagnosis of GBM was a poor prognostic factor for SGS. Patients who underwent gross total resection and chemoradiation had better overall survival outcomes than those who did not. However, during treatment, clinicians should be cognizant of possible extracranial metastases.
资助信息
National Natural Science Foundation of China (81772661); the Natural Science Foundation of Shaanxi Province (2020JZ-30)
资助机构
国家自然科学基金委员会
;
全国哲学社会科学工作办公室
WOS关键词
CENTRAL-NERVOUS-SYSTEM
;
MGMT PROMOTER METHYLATION
;
RECURRENT GLIOBLASTOMA
;
EXTRACRANIAL METASTASES
;
SURVIVAL
;
RESECTION
;
IMPACT
;
EXTENT
;
OLIGODENDROGLIOMA
;
CLASSIFICATION
附件
-
425 Prognostic and predictive factors of secondary gliosarcoma A single-institution series of 18 cases combined with 89 cases from literature.pdf
1.28 MB
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。